We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image
  • Published On : Mar 2022
  • Code : CMI4953
  • Pages :198
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Naloxone is an opioid overdose reversal medicine used to treat morphine and heroin overdoses. It is an opioid antagonist that is classified as a prescription medicine by the U.S. Food and Drug Administration (FDA). Some countries, including Italy and Australia, have reclassified it as an over-the-counter (OTC) drug. Naloxone products are available in a variety of strengths such as 0.4 mg/ml, 1 mg/ml, 0.4 mg/0.4 ml, and 4 mg/0.1 ml. Naloxone is administered in a variety of ways including intranasal, intramuscular, subcutaneous, and intravenous. The most recent medicine in the market is intranasal naloxone product, which can be administered by anyone (non-medical professional). Intravenous products, on the other hand, are mostly administered by trained medical experts.

The U.S. naloxone market is estimated to be valued at US$ 1,390.7 million in 2022 and is expected to exhibit a CAGR of 10.2% during the forecast period (2022-2030).

Figure 1. U.S. Naloxone Market Share in Terms of Value (US$ Mn), By Drug Type, 2022

U.S. NALOXONE MARKET

Increasing product launches in the U.S. is expected to drive the market growth over the forecast period.

The increasing product launches by market players in the country is expected to drive the U.S. naloxone market over the forecast period. For instance, on February 20, 2019, Indivior Plc., a pharmaceutical company announced the launch of Suboxone (buprenorphine and naloxone) sublingual film authorized generic by the U.S. Food and Drug Administration (FDA). The authorized generic is being marketed and distributed on Indivior’s as a representative by Sandoz Inc., a Switzerland based healthcare company has introduced suboxone film is a prescribed medicine indicated for the treatment of opioid dependence and as it is prescribed medicine, it should be used as part of a complete treatment plan to include counseling and psychosocial support.

U.S. Naloxone Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022:

US$ 1,390.7 Mn

Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 10.2% 2030 Value Projection:

US$ 2,909.1 Mn

Geographies covered:
  • Region: North America: U.S. 
Segments covered:
  • By Drug Type: Branded, Generic
  • By Route of Administration: Intranasal Administration, Intramuscular Administration, Intravenous Administration, Others
  • By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar Pharmaceuticals, Inc., INSYS Therapeutics, Inc., Mundipharma International Limited, Kaleo, Inc.,  Kern Pharma, S.L., Samarth Life Sciences Pvt. Ltd., Opiant Pharmaceuticals, Pfizer, Sandoz, and Amneal Pharmaceuticals 

Growth Drivers:
  • Increasing product launches in U.S.
  • Increasing cases of opioid overdose
Restraints & Challenges:
  • Side effects of naloxone

Figure 2. U.S. Naloxone Market Share (%), By Route of Administration, 2022

U.S. NALOXONE MARKET

Increasing cases of opioid overdose in the U.S. is expected to drive demand for its treatment drugs during the forecast period.

Increasing cases of opioid overdose is expected to drive the demand for naloxone products during emergency treatments for treating narcotic overdose, during the forecast period. For instance, according to the data published by the U.S. Department of Health and Human Services (HHS) in 2019, U.S. population around 3.7% i.e. approximately 10.1 million people aged 12 or older misused opioids in the year 2019 and specifically 9.7 million people aged 12 or older misused prescription pain relievers in the year 2019.

U.S. Naloxone Market – Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic is expected to drive growth of the U.S. naloxone market during the forecast period. According to the Coronavirus Disease (COVID-19), Weekly Epidemiological Update by the World Health Organization, over 5,899,578 cases and 11,946 deaths due to coronavirus disease (COVID-19) were reported till February 23, 2022 across the U.S.

Furthermore, increasing opioid cases in the U.S. during the pandemic is expected to drive the U.S. naloxone market over the forecast period According to the article published in National Center for Biotechnology Information (NCBI) about increases in naloxone administrations by Emergency Medical Services Providers during the COVID-19 Pandemic, in May 2021, the opioid crisis in the U.S. may be exacerbated by the COVID-19 pandemic. Increase in opioid use, emergency medical services (EMS) running for opioid-related overdoses, and opioid overdose deaths have been reported in year 2021.

U.S. Naloxone Market: Restraint

The side effects of naloxone is expected to hinder the U.S. naloxone market growth in the near future. For instance, according to Drug.com, naloxone has some adverse effects that include nausea, vomiting, stomach discomfort, fever, sweating, and body aches.

Key Players

Major players operating in the U.S. naloxone include Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar Pharmaceuticals, Inc., INSYS Therapeutics, Inc., Mundipharma International Limited, Kaleo, Inc., Kern Pharma, S.L., Samarth Life Sciences Pvt. Ltd., Opiant Pharmaceuticals, Pfizer, Sandoz, and Amneal Pharmaceuticals.

Frequently Asked Questions

The U.S. naloxone is estimated to be valued at US$ 1,390.7 million in 2022 and is expected to exhibit a CAGR of 10.2 % between 2022 and 2030.

Increasing product launches in U.S. is expected to drive the market growth during the forecast period.

Generic drug segment is expected to hold a major market share during the forecast period in the drug type segment.

The major factor hampering growth of the market include side effects of naloxone.

Major players operating in the market include Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar Pharmaceuticals, Inc., INSYS Therapeutics, Inc., Mundipharma International Limited, Kaleo, Inc., Kern Pharma, S.L., Samarth Life Sciences Pvt. Ltd., Opiant Pharmaceuticals, Pfizer, Sandoz, and Amneal Pharmaceuticals.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo